MACI

This brand name is authorized in Estonia, Ireland, Lithuania.

Active ingredients

The drug MACI contains one active pharmaceutical ingredient (API):

1	Autologous chondrocytes UNII D5P3K3V822 - AUTOLOGOUS CULTURED CHONDROCYTES
	Autologous chondrocyte implantation (ACI) is based on the extraction of the patient’s own chondrocytes isolated from healthy cartilage, their culture in vitro and their subsequent implantation into the cartilage defect. The implantation suspension is cultured and implanted as three-dimensional spheroids.
	Read more about Autologous chondrocytes

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MACI Implantation matrix	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M09AX02		M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system
Discover more medicines within M09AX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1619490
LT	Valstybinė vaistų kontrolės tarnyba	1070788, 1070789